V

Varian

Tech-enabled radiation oncology hardware and software

Hemostasis Sales Specialist

Full-Time
$99.2k - $136.4k+ Commission
Expert
Bachelor's
New Orleans, LA, USA
RemoteMust reside within the assigned territory and travel up to 75%.
Sales & Account ManagementField Sales
Company Historically Provides H1B Sponsorship

About the job

Requirements
  • A bachelor's degree or equivalent experience is required.
  • At least 8 years of progressive sales experience in clinical diagnostics, laboratory solutions, medical devices, hospital sales, healthcare systems, specialty diagnostics, strategic accounts, or corporate account management is preferred.
  • Demonstrated success leading enterprise-level sales engagements across hospital systems, integrated delivery networks, reference laboratories, academic medical centers, and corporate accounts, with the ability to influence executive, operational, clinical, information technology, laboratory, finance, and procurement stakeholders is required.
  • Deep commercial expertise in capital equipment, automation, informatics, reagents, consumables, and connected diagnostic solutions is required.
  • Experience using customer relationship management (CRM) tools is required.
  • Ability to travel up to 75% to support customer and business needs is required.
  • Ability to lead without authority, work across cross-functional teams, influence internal prioritization, and drive accountability across complex, matrixed commercial pursuits is required.
  • Communication, presentation, relationship-building, stakeholder engagement, and consultative selling skills are required, including the ability to translate hemostasis science, laboratory workflow, automation, informatics, and financial impact into differentiated business value for senior decision-makers.
  • A record of exceeding growth objectives, expanding market share, displacing competitors, advancing strategic opportunities, and building sustainable customer partnerships through disciplined account planning and commercial execution is required.
  • Computer skills, including Outlook, Excel, and PowerPoint, are required.
  • Candidates must reside within the assigned territory and meet travel requirements.
  • A valid driver's license in the state of residence is required; applicants may not have prior DUI/DWI convictions, pending DUI/DWI charges, or other serious moving violations unless prohibited by law.
  • Candidates must be able to work with controlled technology in accordance with United States export control law.
  • Candidates must meet applicable client vendor-credentialing requirements for site access and maintain those requirements during employment; requirements may include proof of identification, background checks, drug screens, immunizations, annual tuberculosis testing, and healthcare training.
Responsibilities
  • Develop and execute territory and specialty growth strategies for Hemostasis (Coagulation), including enterprise account prioritization, competitive conversion strategy, installed-base expansion, portfolio penetration, and multi-year revenue growth planning.
  • Lead complex and strategically significant sales cycles, including executive discovery, stakeholder mapping, business-case creation, competitive positioning, contract strategy, negotiation support, close planning, and implementation alignment.
  • Cultivate executive sponsorship and trusted-advisor relationships with C-suite, laboratory, clinical, procurement, operations, information technology, finance, and health system leaders to influence enterprise decision-making and position Siemens Healthineers as the preferred strategic partner in hemostasis/coagulation testing.
  • Build integrated automation and informatics value propositions tied to Siemens Healthineers equipment, demonstrating how connected solutions improve throughput, standardization, operational efficiency, clinical confidence, and customer financial outcomes.
  • Orchestrate complex, matrixed team-selling motions across Diagnostics Sales, Strategic Accounts, Marketing, Scientific Affairs, Technical Applications, Informatics, Service, Finance, Contracting, and implementation teams to deliver a coordinated enterprise customer strategy.
  • Own disciplined commercial execution for a senior territory portfolio, including advanced funnel management, opportunity risk assessment, forecast accuracy, customer relationship management governance, strategic account planning, business reviews, and escalation of barriers to growth.
  • Serve as the regional Hemostasis (Coagulation) subject matter expert within a matrixed organization, shaping strategic pursuits, supporting launch readiness, elevating competitive intelligence, and influencing specialty portfolio growth priorities.
  • Quantify customer impact, including operational efficiency, labor utilization, standardization, analyzer productivity, assay consolidation, cost-to-serve, revenue opportunity, risk reduction, and total value of ownership.
  • Build executive-level growth plans for priority accounts that expand share, protect at-risk business, create referenceable customers, strengthen long-term loyalty, and deliver measurable commercial, operational, and clinical outcomes.
Desired Qualifications
  • An advanced degree is preferred.
  • Direct Hemostasis (Coagulation) experience is strongly preferred; hematology, plasma protein, or broader laboratory diagnostics experience is valued.
  • Experience using Miller Heiman is a plus.

About the company

Varian, part of Siemens Healthineers, focuses on oncology by providing integrated radiation oncology solutions that combine software, hardware, patient data, and care teams. Its offerings include treatment-planning software, radiation therapy machines, and data-management systems that work together to enable precise cancer treatments. The company differentiates itself through an integrated platform approach and services like Oncology-as-a-Service (OaaS), which lets healthcare providers adopt advanced radiation oncology with ongoing service support rather than large upfront investments. Varian serves healthcare providers such as hospitals and cancer centers, helping them deliver coordinated care and improve patient outcomes. Its goal is to reduce the fear of cancer by using data and technology to support clinicians in delivering effective treatments.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

1948

Get referred to Varian

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ARPA-H awarded Varian up to $60 million in April 2026 for FLASH-RT.
  • FDA cleared TrueBeam for osteoarthritis in March 2026, opening a non-cancer market.
  • Telix collaboration and 2026 AI approvals expand Varian's clinical and software pipeline.

What critics are saying

  • RaySearch enabled online adaptive TrueBeam workflows in Belgium in May 2026, eroding software differentiation.
  • Elekta still attacks Varian's lead in adaptive radiotherapy and premium MR-guided care.
  • If FLASH and non-oncology bets fail by 2028, Varian becomes a commoditized linear-accelerator vendor.

What makes Varian unique

  • Siemens Healthineers gives Varian imaging, radiotherapy, and capital-sales integration globally.
  • Varian's 2026 CE-marked Eclipse AI contouring deepens workflow lock-in across planning.
  • TrueBeam, Halcyon, and Ethos create an installed-base moat hospitals rarely replace.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours
  • Remote Work Options
  • Paid Vacation
  • Paid Holidays
  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Wellness Program
  • 401(k) Retirement Plan

Growth & Insights and Company News

6 month growth

3%

1 year growth

3%

2 year growth

3%
Varex Imaging Corporation
Sep 14th, 2026
About Us | Varex Imaging Corporation

We strive to help customers become world-class system suppliers by strengthening their competitiveness and enabling them to bring products to market faster

MEDQOR
Apr 30th, 2026
Siemens Healthineers secures $83M to develop photon Flash radiotherapy for cancer treatment

Siemens Healthineers has received up to $60 million from the US Advanced Research Projects Agency for Health to develop photon Flash radiotherapy, with the company contributing an additional $23 million, totalling $83 million over five years. Flash photon therapy delivers radiotherapy more than 100 times faster than current technologies, aiming to reduce side effects and improve healthy tissue sparing. Unlike proton and electron beam platforms, which face scalability challenges, photon beams are the standard of care for over 50% of cancer patients. The project will build on existing C-arm linear accelerators to enable broader clinical access. Siemens Healthineers aims to transition ultra-high dose rate radiotherapy from experimental treatment into global standard of care within the five-year timeframe.

Business Wire
Mar 19th, 2026
Varian TrueBeam gets FDA clearance for low-dose radiotherapy to treat osteoarthritis

Siemens Healthineers has received FDA 510(k) clearance for its Varian TrueBeam radiotherapy systems to treat medically refractory osteoarthritis in adults using low-dose radiation therapy. This marks the first expansion of Varian's radiotherapy platform beyond cancer care into chronic musculoskeletal conditions. Osteoarthritis affects over 33 million adults in the US and approximately 600 million globally. The clearance covers TrueBeam, TrueBeam STx, VitalBeam and Edge systems, offering patients with persistent pain a non-invasive outpatient treatment option that targets inflammation, reduces pain and improves joint function. The approval builds on Varian's previous regulatory clearances for non-oncological indications, including radiosurgery treatment for medically refractory essential tremor. The TrueBeam platform combines high-resolution imaging with precise dose control whilst maintaining streamlined clinical workflows.

AuntMinnieEurope.com
Dec 10th, 2025
Telix and Varian enter research collaboration

Telix and Varian enter research collaboration. Telix Pharmaceuticals and Siemens Healthineers' company Varian have agreed to develop novel clinical applications that combine Telix's theranostics products and Varian's external beam radiation therapy (EBRT) technology. The first area of focus will be in identifying opportunities to use Telix's prostate cancer PET imaging agents in selecting patients for EBRT, developing personalized treatment plans (particularly in the context of Varian's Ethos adaptive radiotherapy system), and monitoring responses to treatment, Telix said. The agreement supports both company-sponsored and investigator-led clinical studies. Varian is a key player in EBRT and working with the company will allow Telix to explore how theranostics can be used more effectively by radiation oncologists to enhance patient selection and deliver targeted treatment, Telix noted. I agree to receive marketing related digital communications about products, services, events and offers that may be relevant to my given user preferences and behavior. I agree to share my information with the sponsor. I have read and agree to the privacy policy & terms of service and wish to opt-in.

AuntMinnie.com
Mar 28th, 2025
Varian, Embolx sign image-guided microcatheter agreement

Siemens Healthineers company Varian has entered into a sales and marketing agreement with Embolx for its Sniper Balloon Occlusion Microcatheter.